scholarly journals Protective immunity induced by oral vaccination with a recombinant Lactococcus lactis vaccine against H5Nx in chickens

2022 ◽  
Vol 18 (1) ◽  
Author(s):  
Yi Ren ◽  
Xin Lu ◽  
Zhonghe Yang ◽  
Han Lei
Keyword(s):  
Immune Responses ◽  
Lactococcus Lactis ◽  
Protective Immunity ◽  
Field Application ◽  
Oral Vaccination ◽  
Lethal Challenge ◽  
Disease Symptoms ◽  
Recombinant Lactococcus Lactis ◽  
Chicken Model ◽  
Promising Vaccine Candidate

Abstract Background The development of an influenza vaccine for poultry that provides broadly protective immunity against influenza H5Nx viruses is a challenging goal. Results Lactococcus lactis (L. lactis)/pNZ8149-HA1-M2 expressing hemagglutinin-1 (HA1) of A/chicken/Vietnam/NCVD-15A59/2015 (H5N6) and the conserved M2 gene of A/Vietnam/1203/2004 (H5N1) was generated. L. lactis/pNZ8149-HA1-M2 could induce significant humoral, mucosal and cell-mediated immune responses, as well as neutralization antibodies. Importantly, L. lactis/pNZ8149-HA1-M2 could prevent disease symptoms without significant weight loss and confer protective immunity in a chicken model against lethal challenge with divergent influenza H5Nx viruses, including H5N6 and H5N1. Conclusions L. lactis/pNZ8149-HA1-M2 can serve as a promising vaccine candidate in poultry industry for providing protection against H5Nx virus infection in the field application.

scholarly journals Oral vaccination of mice against tetanus with recombinant Lactococcus lactis

1997 ◽  
Vol 15 (7) ◽  
pp. 653-657 ◽  
Author(s):  
Karen Robinson ◽  
Lisa M. Chamberlain ◽  
Karin M. Schofield ◽  
Jeremy M. Wells ◽  
Richard W.F. Le Page
Keyword(s):  
Lactococcus Lactis ◽  
Oral Vaccination ◽  
Recombinant Lactococcus Lactis

Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env

Blood ◽  
2003 ◽  
Vol 102 (1) ◽  
pp. 223-228 ◽  
Author(s):  
Ke-Qin Xin ◽  
Yuka Hoshino ◽  
Yoshihiko Toda ◽  
Shizunobu Igimi ◽  
Yoshitsugu Kojima ◽  
...  
Keyword(s):  
Immune Responses ◽  
Lactococcus Lactis ◽  
Potential Role ◽  
Protective Efficacy ◽  
Oral Immunization ◽  
Vaccine Strategy ◽  
Regional Lymph Nodes ◽  
Viral Loads ◽  
Recombinant Lactococcus Lactis ◽  
Further Development

Abstract This study investigates whether genetically modified orally administered Lactococcus lactis (L lactis) could be used as an HIV vaccine. L lactis is immunogenic and extremely safe when delivered orally. We created a recombinant L lactis vector expressing the envelope protein of HIV on its cell surface. Oral immunization with this vector induced high levels of HIV-specific serum IgG and fecal IgA antibodies. Cell-mediated immune responses also were generated in both the regional lymph nodes and the spleen. Dendritic cells are readily infected by L lactis and appear to play a potential role in mediating the development of these immune responses. The protective efficacy of this vaccine strategy was demonstrated by challenging mice intraperitoneally with an HIV Env–expressing vaccinia virus. Their viral loads were 350-fold lower than those of control mice. These findings support the further development of L lactis–based HIV vaccines. (Blood. 2003; 102:223-228)

Sign in / Sign up

Export Citation Format

Share Document